Together, we’ve formed the Translational Oncology Research Hub with King’s College London to provide insight into how patients respond to cancer treatment, using novel machine learning to analyse high-risk patients, integrating genetic and molecular traits, and ultimately make better predictions for better outcomes.
This is just one way we’re looking to expand the scale, scope, and power of human ingenuity and pair it with advanced technology to tackle the most complex drug discoveries so the world can get ahead of disease.
Kim Branson, Global Head of Artificial Intelligence and Machine Learning at GSK, sums up the approach to incorporate technology as a means for discovering solutions to diseases like cancer.
